SCHEMBL3353149

SCHEMBL3353149

COc1ccc2nc(C)c(-c3csc(C4(c5ccc(C(=O)NO)cc5)CCCC4)n3)n2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 4/20 0.38
HDAC6 Q9UBN7 3/20 0.38
HDAC3 O15379 2/20 0.38
HDAC2 Q92769 2/20 0.38
BACE1 P56817 2/20 0.38
AKT1 P31749 4/20 0.38
AKT2 P31751 4/20 0.38
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
KMT2A Q03164 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HDAC4 P56524 1/20 0.34
HDAC7 Q8WUI4 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC9 Q9UKV0 1/20 0.34
HDAC5 Q9UQL6 1/20 0.34
KDM4E B2RXH2 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3352693 0.97 CA1 (0.38) HDAC1HDAC6HDAC3HDAC2AKT1
SCHEMBL197185 0.93 F2RL3 (0.39) AKT1AKT2CA1CA2MEN1
SCHEMBL3352993 0.91 AKT1 (0.36) HDAC1HDAC6HDAC3HDAC2BACE1
SCHEMBL3351453 0.89 HDAC1 (0.40) HDAC1HDAC6AKT1AKT2HDAC4
SCHEMBL3350568 0.88 ALDH1A1 (0.39) HDAC1HDAC6BACE1AKT1AKT2
SCHEMBL3350417 0.88 HDAC1 (0.45) HDAC1HDAC6HDAC3HDAC2KMT2A
SCHEMBL3351646 0.88 AKT1 (0.35) HDAC1HDAC6HDAC3HDAC2AKT1
SCHEMBL3350415 0.87 HDAC1 (0.39) HDAC1HDAC6HDAC3HDAC2BACE1
SCHEMBL3352524 0.86 AKT1 (0.38) HDAC1HDAC6HDAC3HDAC2AKT1
SCHEMBL3352409 0.86 AKT1 (0.48) HDAC1HDAC6AKT1AKT2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198299-B2 Cycloalkylidene and heterocycloalkylidene inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-06-12 US claimed
US-20100022543-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-01-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022543-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC2 HDAC1 1/4885HDAC6 7/4885HDAC3 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.